The fund's investment objective is to achieve income with the potential for some capital growth from a portfolio made up mainly of the securities of UK companies.
Name | % Net Assets |
---|---|
BG Group PLC | 6.6% |
AstraZeneca PLC | 6.5% |
GlaxoSmithKline PLC | 6.1% |
Vodafone Group PLC | 6.0% |
Imperial Tobacco Group PLC | 5.2% |
British American Tobacco PLC | 4.7% |
Royal Dutch Shell PLC | 4.1% |
Centrica PLC | 4.0% |
Roche Holding AGCFD | 3.5% |
BT Group PLC | 3.4% |
Key | % Net Assets |
---|---|
BG Group PLC | 6.6% |
AstraZeneca PLC | 6.5% |
GlaxoSmithKline PLC | 6.1% |
Vodafone Group PLC | 6.0% |
Other | 74.8% |
Date | 13-Nov-2024 |
---|---|
NAV | 84.12p |
Currency | GBP |
Change | -0.47p |
% | -0.56% |
YTD change | -3.56p |
YTD % | -4.06% |
Fund Inception | 02/02/2009 |
---|---|
Fund Manager | n/a |
TER | 1.75 (28-Feb-2012) |
Minimum Investment | |
---|---|
Initial | n/a |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | 3.50% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
No risk data available. |
You are here: research